CTLA4 and neoplasm: This was important for the therapeutic efficacy of ICB as,in contrast to parental KPAR tumours, anti-CTLA-4 failed to result in long-termdurable regression of Emv2-/- KPAR subcutaneoustumours (Supplementary Fig.8C).